Agility Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-12-2024
- Paid Up Capital ₹ 0.50 M
as on 16-12-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 5.00 M
as on 16-12-2024
- Revenue -88.68%
(FY 2020)
- Profit 30.59%
(FY 2020)
- Ebitda 139.86%
(FY 2020)
- Net Worth -95.31%
(FY 2020)
- Total Assets -25.43%
(FY 2020)
About Agility Biotech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.00 M.
Naveen Sangwan and Saroj Sangwan serve as directors at the Company.
- CIN/LLPIN
U24233HR2010PTC040196
- Company No.
040196
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2010
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Rohtak, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Agility Biotech Private Limited offer?
Agility Biotech Private Limited offers a wide range of products and services, including Medical Consultancy Services, Custom Antibody Services, Business Consultant, Business Plan Service, Medical Consultants & Clinics, Nutraceuticals & Dietary Supplements, Dietary Supplements, Lubricants, Insecticides, Biopesticides.
Who are the key members and board of directors at Agility Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveen Sangwan  | Director | 09-Mar-2010 | Current |
| Saroj Sangwan | Director | 23-Dec-2019 | Current |
Financial Performance of Agility Biotech.
Agility Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 88.68% decrease. The company also saw a substantial improvement in profitability, with a 30.59% increase in profit. The company's net worth observed a substantial decline by a decrease of 95.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agility Biotech?
In 2018, Agility Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 10 Nov 2014 | ₹5.00 M | Open |
How Many Employees Work at Agility Biotech?
Unlock and access historical data on people associated with Agility Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agility Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agility Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
